GlobeNewswire by notified

Rovsing A/S to issue new shares and to issue warrants

Share

ROVSING A/S TO ISSUE NEW SHARES AND TO ISSUE WARRANTS

Today, the board of directors has exercised its current authorizations to (i) increase Rovsing’s share capital with a nominal value of up to DKK 149,350 and (ii) to issue a total of 23,660 warrants to members of the board of directors, the management and employees.

In the light of a solid orderbook, which can form the framework for continued growth the board of directors have decided to issue a warrant program to maintain key competencies in the Company and to support the Company’s growth ambition.

Issue of new shares
Today, the board of directors of Rovsing A/S (“Rovsing”) has exercised its authorization to increase the share capital without pre-emption rights for Rovsing’s existing shareholders according to article 5.1(b) of the articles of association.

The board of directors has resolved to issue up to 2,987 new shares (corresponding to a nominal value of DKK 149,350 at a subscription price of DKK 57,80 per share corresponding to gross proceeds of approximately DKK 172,650. The subscription price of DKK 57,80 per share corresponds to the average of the average share price for the five days prior to the date on which the board of directors decided to issue the new shares.

The new shares will be subscribed by members of the board of directors, management, and employees of Rovsing. The total subscription amount of DKK 172,650 shall be paid to Rovsing no later than 29 November 2022 at 12:00 (CET).

Registration of capital increase
Subject to settlement, the new shares issued as a result of the capital increase will be registered with the Danish Business Authority, and the number of shares and votes will increase by 2,987 shares to 476,228 shares each with a nominal value of DKK 50.00. Rovsing will have a registered share capital of nominal DKK 23,811,400 following registration of the capital increase.

The new shares represent approximately 0.631% of Rovsing’s registered share capital before the capital increase and 0.627% of Rovsing’s share capital after the capital increase.

The new shares will rank pari passu with the existing shares in Rovsing. The new shares will be negotiable instruments, and no restrictions will apply to their transferability. No shares, including the new shares, carry any special rights. The rights conferred by the new shares, including voting and dividend rights, will apply from the date when the capital increase is registered with the Danish Business Authority. The new shares are to be registered in the name of the holder in Rovsing’s register of shareholders.

The board of directors has accordingly exercised a total nominal value of DKK 20.118.846,95 out of the total authorization of nominal DKK 30,000,000 in connection with the directed issue.

Expected timetable
Settlement and payment for the new shares is expected to take place on or before 29 November 2022. Registration of the capital increase with the Danish Business Authority is expected to take place on or before 30 November 2022. Following the registration, the new shares are expected to be admitted to trading on Nasdaq Main Market Copenhagen no later than 2 December 2022 under the ISIN code of Rovsing’s existing shares (DK0061152170).

Issue of warrants
The board of directors has today exercised its authorization to issue a total of 23,660 warrants to members of the board of directors, management and employees. Each warrant entitles the warrant holder to subscribe for new shares in Rovsing, each with a nominal value of DKK 50.00, which in total corresponds to a total nominal value of DKK 1.183.000. The warrants are issued in accordance with section 6 of the articles of association.

The exercise price is fixed at DKK 57,80 per share of nominal DKK 50.00 corresponding to the average of the average share price for the five days prior to the date on which the board of directors decided to issue the warrants.

The warrants will vest in 24 equal monthly installments with the first installment vesting from 24 October 2022. Warrants can be exercised from 24 October 2024 until 1 January 2025 starting from the day after all the warrant holder’s warrants are fully vested.

Warrants that have not been exercised no later than on last day of the exercise period set out above will lapse automatically.

The warrants include conditions on accelerated vesting in case of a sale of the entire share capital of the company, a single shareholder becoming a shareholder with 20% or more of the company’s share capital, or a share exchange of the entire share capital.

Following the issue of warrants the board of directors’ authorization to issue warrants pursuant to section 6 of the articles of association is fully exercised.

Further information:

Sigurd Hundrup, CFO. Tel. +45 53 39 18 92. Email: shu@rovsing.dk

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Golar LNG Limited - Announcement of filing of Form 20-F Annual Report28.3.2024 22:47:27 CET | Press release

Golar LNG Limited announces that it has filed its Form 20-F for the year ended December 31, 2023 with the Securities and Exchange Commission in the U.S. Form 20-F can be downloaded from the link below, is available on our website (www.golarlng.com) and shareholders may receive a hard copy free of charge upon request. March 28, 2024 The Board of Directors Hamilton, Bermuda Enquiries: Golar Management Limited: + 44 207 063 7900 Stuart Buchanan This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment GLNG 2023 Annual Report Form 20-F

Magna Posts 2023 Annual Report28.3.2024 22:26:07 CET | Press release

AURORA, Ontario, March 28, 2024 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG; NYSE: MGA) today announced that its 2023 Annual Report, including Management’s Discussion and Analysis and Audited Consolidated Financial Statements, Annual Information Form (AIF) and Form 40-F, are now available on the company’s website, www.magna.com. Magna has also filed these documents with the Canadian Securities Administrators (accessible through its website at www.sedarplus.ca) and the U.S. Securities and Exchange Commission (accessible through its website at www.sec.gov/edgar). Our 2024 Annual Meeting of Shareholders will be held on Thursday, May 9, 2024, commencing at 10:00 a.m. (Eastern Daylight Time). The meeting is being conducted as a virtual-only meeting accessible at www.virtualshareholdermeeting.com/MGA2024. Magna will provide a paper copy of its audited financial statements as contained in our 2023 Annual Report to Shareholders, free of charge, on request through our website, www.mag

Fortuna files Form 40-F, Annual Report28.3.2024 22:00:00 CET | Press release

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that the Company has filed today its fiscal 2023 annual report on Form 40-F with the U.S. Securities and Exchange Commission (“SEC”). The Form 40-F, which includes the Company’s fiscal 2023 annual audited financial statements, management’s discussion and analysis, and annual information form, is available on the Company’s website and on the SEC´s website. Printed copies of the annual financial statements are available free of charge to Fortuna shareholders upon written request. About Fortuna Silver Mines Inc. Fortuna Silver Mines Inc. is a Canadian precious metals mining company with five operating mines in Argentina, Burkina Faso, Côte d'Ivoire, Mexico, and Peru. Sustainability is integral to all our operations and relationships. We produce gold and silver and generate shared value over the long-term for our stakeholders through efficient production, environmental p

Nokia Corporation: Repurchase of own shares on 28.03.202428.3.2024 21:30:00 CET | Press release

Nokia Corporation Stock Exchange Release 28 March 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 28.03.2024 Espoo, Finland – On 28 March 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL467,1243.29CEUX--BATE--AQEU--TQEX--Total467,1243.29 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 202328.3.2024 21:28:47 CET | Press release

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024 LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47)for the treatment of solid tumors BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023. “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “We are laser focused on executing the PRESent registrational studies for SerpinPC, a potential first-in-class subcutaneously administered therapy with a differentiated safety profile for individuals with he

HiddenA line styled icon from Orion Icon Library.Eye